Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Real world treatment patterns of first-line combination therapies among BRAF+ metastatic melanoma patients.
Authors
Sameer Ghate
Novartis Pharmaceuticals Corporation, East Hanover, NJ
Sameer Ghate, Jackson Tang, Zhiyi Li, Antonio Reis Nakasato
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 197)
DOI
10.1200/JCO.2018.36.5_suppl.197
Abstract #
197
Poster Bd #
K6
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Real world treatment patterns of first-line combination therapies among BRAF+ metastatic melanoma patients stratified by tumor burden.
First Author: Sameer Ghate
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Real-world time to next treatment (TTNT) for first-line (1L) targeted and immuno-oncology therapies for BRAF-mutated metastatic melanoma (MM) by lactate dehydrogenase (LDH) level.
First Author: Jason J. Luke
Poster
2022 ASCO Annual Meeting
Clinical predictors of longer survival in patients with BRAFV600-mutated metastatic melanoma receiving immunotherapy prior to BRAF/MEK inhibition in the metastatic setting.
First Author: Adriana Matutino Kahn
Poster
2021 ASCO Annual Meeting
Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma.
First Author: Max Jameson-Lee